News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中國生物製藥(01177.HK)創新藥TQB3205臨床試驗申請獲批
中國生物製藥(01177.HK)公布，附屬正大天晴自主研發的創新藥TQB3205「Pan-KRAS抑制劑」 已獲得美國食品藥品監督管理局(FDA)的新藥臨床試驗(IND)批准，用於晚期惡性腫瘤。(ca/w)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
中國生物製藥(01177.HK)創新藥TQB3205臨床試驗申請獲批
Close
Recommend
21
Positive
31
Negative
10
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

中國生物製藥(01177.HK)  +0.070 (+1.215%)    Short selling $89.78M; Ratio 20.236%   公布，附屬正大天晴自主研發的創新藥TQB3205「Pan-KRAS抑制劑」 已獲得美國食品藥品監督管理局(FDA)的新藥臨床試驗(IND)批准，用於晚期惡性腫瘤。(ca/w)
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-14 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.